Roche has been accelerating its obesity pipeline strategy through a series of high-value partnerships designed to compete in the fast-growing weight-loss drug market.
The Swiss pharmaceutical giant struck a deal worth up to $2.5 billion with Hanmi Pharmaceuticals as part of its broader push to build out obesity drug candidates.
Roche also entered a $5.3 billion partnership with Zealand Pharmaceuticals, underlining just how aggressively the company is pursuing next-generation metabolic disease treatments.
The obesity drug market has become one of the most competitive arenas in global pharmaceuticals, with major players racing to develop alternatives to the dominant GLP-1 class of treatments.
Meanwhile, Akeso, the Chinese biotech behind the cancer drug ivonescimab, has faced mounting questions over the reliability of its clinical trial data generated exclusively within China.
Evaluate Pharma has placed the net present value of ivonescimab, co-developed with Summit Therapeutics, at over $25 billion, making it one of the most valuable pipeline assets in oncology.
Akeso chief executive Michelle Xia has moved to defend the company’s data and the broader translatability of China-only trial results to Western patient populations and regulatory standards.
The scrutiny of Chinese biotech firms has intensified considerably in Washington, with U.S. lawmakers pushing to restrict Chinese pharmaceutical companies from accessing federal contracts.
Language targeting Chinese biotechs has been proposed for inclusion within the National Defense Authorization Act, reflecting bipartisan concern over reliance on Chinese-origin drug development.
The legislative push mirrors wider industry debate about how to assess and trust clinical data produced in China as that country’s biopharma sector grows in global influence and ambition.
The Biosecure Act and related congressional efforts have placed firms like Akeso under a new kind of pressure that goes well beyond scientific peer review or regulatory approval processes.
Analysts and industry observers have increasingly described 2026 as a pivotal year for determining how Western markets integrate, or push back against, Chinese pharmaceutical innovation at scale.